Dr. Martens plc
DOCMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.21 | -0.27 | -0.41 | 0.03 |
| FCF Yield | 35.22% | 16.19% | 1.38% | 6.04% |
| EV / EBITDA | 6.81 | 6.25 | 8.63 | 9.87 |
| Quality | ||||
| ROIC | 3.68% | 11.01% | 17.90% | 27.18% |
| Gross Margin | 64.97% | 57.34% | 56.37% | 59.68% |
| Cash Conversion Ratio | 43.62 | 2.43 | 0.56 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.66% | -1.16% | 8.97% | 10.55% |
| Free Cash Flow Growth | 27.31% | 587.19% | -86.34% | 15.37% |
| Safety | ||||
| Net Debt / EBITDA | 2.25 | 1.86 | 1.41 | 0.62 |
| Interest Coverage | 1.92 | 3.93 | 10.20 | 15.51 |
| Efficiency | ||||
| Inventory Turnover | 1.47 | 1.47 | 1.69 | 2.98 |
| Cash Conversion Cycle | 237.86 | 238.75 | 196.67 | 94.24 |